FDA ( Food and Drug Administration ) approved Revatio ( Sildenafil ) as a treatment for pulmonary arterial hypertension ( PAH ), a rare, aggressive and life-shortening vascular disease. Sildenafil is ...

Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening, in adults who are temporarily unable to take oral Revatio. Give by IV bolus injection.